30 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
that is noninvasive and offers particular benefit during a public healthcare crisis like the coronavirus pandemic.
Research and Development Activities … may be longer. The COVID-19 pandemic significantly increased the FDA’s workload because of the need to review emergency use authorization requests
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
pandemic.
Research and Development Activities
We are continuing our research and development activities pertaining to diagnostics that include … require advisory committee input, and in practice may be longer. The COVID-19 pandemic significantly increased the FDA’s workload because of the need
424B5
BIAF
BioAffinity Technologies Inc
8 Mar 24
Prospectus supplement for primary offering
12:18pm
results will suffer if we fail to compete effectively; and
our business is affected by the ongoing COVID-19 pandemic and may be significantly adversely … affected as the pandemic continues or if other events out of our control disrupt our business or that of our third-party providers.
The Securities We May
424B5
kvpkphy3w 4adrdhu
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
fizkzr 9kjcrg
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
12pr7u
16 Nov 23
Shelf registration
5:23pm
DRS
6riyhnfv tk1
14 Aug 23
Draft registration statement
12:00am
10-K
n5ybew2sg5
31 Mar 23
Annual report
3:40pm
10-Q
h2lu v5b79nacuum
14 Nov 22
Quarterly report
5:11pm
8-K
EX-1.1
ux8449y17
6 Sep 22
Entry into a Material Definitive Agreement
1:15pm
424B4
6kt9h8itlt63x0rnj6
2 Sep 22
Prospectus supplement with pricing info
3:25pm